PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.99%
R&D growth above 1.5x TRAW's 26.48%. Michael Burry would check for spending discipline.
-4.08%
G&A reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
80.19%
Other expenses change of 80.19% while TRAW maintains costs. Bruce Berkowitz would investigate efficiency.
21.99%
Operating expenses growth 50-75% of TRAW's 40.84%. Bruce Berkowitz would examine efficiency.
21.99%
Total costs growth 50-75% of TRAW's 40.84%. Bruce Berkowitz would examine efficiency.
No Data
No Data available this quarter, please select a different quarter.
80.19%
D&A growth while TRAW reduces D&A. John Neff would investigate differences.
32.89%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-21.99%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
198.65%
Other expenses growth less than half of TRAW's 9433.33%. David Dodd would verify if advantage is sustainable.
32.68%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.68%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
32.51%
EPS change of 32.51% while TRAW is flat. Bruce Berkowitz would examine quality.
32.51%
Diluted EPS change of 32.51% while TRAW is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.